Abstract. Mathematical models have proven valuable in understanding the dynamics of HIV-1 infection in vivo. By comparing these models to data obtained from patients undergoing antiretroviral drug therapy, it has been possible to determine many quantitative features of the interaction between HIV-1, the virus that causes AIDS, and the cells that are infected by the virus. The most dramatic nding has been that even though AIDS is a disease that occurs on a time scale of about 10 years, there are very rapid dynamical processes that occur on time scales of hours to days, as well as slower processes that occur on time scales of weeks to months. We show how dynamical modeling and parameter estimation techniques have uncovered these important features of HIV pathogenesis and impacted the way in which AIDS patients are treated with potent antiretroviral drugs.
Introduction. Infection by human immunode ciency virus-type 1 (HIV-1)
has many puzzling quantitative features. For example, there is an average lag of nearly 10 years between infection with the virus and the onset of AIDS in adults. The reason for this time lag remains largely unknown, although it seems tied to changes in the number of circulating CD4 + T cells. The major target of HIV infection is a class of lymphocytes or white blood cells known as CD4 + T cells. These cells secrete growth and di erentiation factors that are required by other cell populations in the immune system, and hence these cells are also called \helper T cells". When the CD4 + T cell count, which is normally around 1000 mm ?3 , reaches 200 mm ?3 or below in an HIV-infected patient then that person is classi ed as having AIDS. Because of the central role of CD4 + T cells in immune regulation, their depletion has widespread deleterious e ects on the functioning of the immune system as a whole and leads to the immunode ciency that characterizes AIDS.
The reason for the fall in the T cell count is unknown, as are the processes that determine the rate of fall. T cells are normally replenished in the body, and the infection may a ect the source of new T cells or the homeostatic processes that control T cell numbers in the body. Although HIV can kill cells that it productively infects, only a small fraction of CD4 + T cells (10 ?4 to 10 ?5 ) are productively infected at any one time. Thus, in addition to direct killing of T cells, HIV may have many indirect e ects 2, 43] .
Over the past decade, a number of models have been developed to describe the immune system, its interaction with HIV, and the decline in CD4 + T cells. Both stochastic and deterministic models have been developed. Stochastic models 41, 42, 64] can be used to account for the early events in the disease, when there are few infected cells and a small number of viruses, or situations where the variability among individuals is of interest. One class of stochastic models has looked at the e ects of increasing variability among viral strains, as a means of escaping control by the immune system, in the progression to AIDS 44, 45, 46, 48] , but this approach has been criticized. 63, 68] . Deterministic models, which have been developed by many authors 1, 10, 12, 15, 17, 18, 25, 26, 27, 29, 30, 31, 32, 33, 37, 38, 39, 40, 49, 54, 56, 57, 59, 61, 62, 66] , examine the changes in mean cell numbers, and are more applicable to later stages of the process in which population sizes are large. These models typically consider the dynamics of the CD4 + T cell and virus populations as well as the e ects of drug therapy. In some of these models other immune system populations, such as macrophages or CD8 + cells, have been included. Many of these models, and particularly ones developed before 1995, have tended to focus on explaining the kinetics of T cell decline. Unfortunately, many di erent models have been able to, more or less, mimic this aspect of HIV infection, and to make progress additional criteria needed to be developed. The impetus for further modeling came with the development of rapid, sensitive, and accurate methods of measuring the number of virus particles in blood. Each virus particle contains two RNA molecules that can be measured by quantitative polymerase chain reaction (PCR) based methods. Thus, in addition to mimicking changes in T cell kinetics current models also need to account for the change in the amount of virus detected in blood and possibly other tissues and bodily uids. Further, experimental methods have been developed that can measure, albeit with less accuracy than the PCR-based methods, the number of infected cells in a tissue or blood sample 6, 19, 51] . Thus, theories also need to explain the dynamical changes in the number of infected cells.
In this article we review recent developments in which modeling has made a substantial impact on our thinking and understanding of HIV infection. Because of di culties of doing experiments in humans, fundamental information has been lacking about the dynamics of HIV infection. For example, because the disease takes 10 years, on average to develop, many people thought that the components of the disease process would also be slow. This has turned out to be incorrect. As we show, modeling combined with appropriate experiments has revealed that HIV is a dynamic disease encompassing a number of di erent time scales, running from hours to days to weeks to months. We show how perturbation experiments ,combined with mathematical modeling, lead to the uncovering of these di erent time scales and to the recognition that these time scales correspond to important biological processes underlying HIV infection. Further, the analysis of such in vivo perturbation experiments has helped elucidate the nature of various reservoirs for the virus and raised for serious discussion the intriguing possibility that prolonged therapy with highly e ective drug combinations might ultimately lead to virus eradication. The fact that HIV replicates rapidly, producing on average 10 10 viral particles per day, which was uncovered by this approach, led to the realization that HIV was evolving so rapidly that treatment with a single drug was bound to fail. This realization helped speed the recommended form of treatment from monotherapy to combination therapy employing three or more drugs, and has had a major impact in extending people's lives. While virus eradication, no longer seems like an easily attainable goal even for patients on combination therapy, modeling still brought home an important practical message -patients should continue taking antiretroviral drugs for a period of at least 2 { 3 years after virus is no longer detectable in blood. Lastly, mathematical modeling, which at one time was essentially ignored by the experimental AIDS community, has in the last three years become an important tool and almost all of the major experimental groups are now collaborating with a theorist.
In order to understand the successes of modeling we begin with an overview of the dynamical features of HIV infection as understood in the early 1990's. The typical course of HIV infection as might have been seen in a textbook 67] or review article is shown in Figure 1 .1. Immediately after infection the amount of virus detected in the blood, V , rises dramatically. Along with this rise in virus, u-like symptoms tend to appear. After a few weeks to months the symptoms disappear and the virus concentration falls to a lower level. An immune response to the virus occurs and antibodies against the virus can be detected in the blood. A test to detect these antibodies is used to determine if a person has been exposed to HIV. If the antibodies are detected, a person is said to be HIV-positive. The viral load and level of antibodies against HIV are depicted. The early peak in viral load corresponds to primary infection. Primary infection is followed by a long asymptomatic period during which the viral load changes little. Ultimately, the viral load increases and the symptoms of full-blown AIDS appear. On average the time from infection to AIDS is ten years, but still some patients progress to AIDS much more rapidly, while others progress more slowly. The graphs here are only meant to be schematic and are not data from any particular patient.
The level the virus falls to after \primary infection" has been called the setpoint. The viral concentration deviates little from this set-point level for many years; however, the concentration of CD4 + T cells measured in blood slowly declines. This period in which the virus concentration stays relatively constant but in which the Tcell count slowly falls is typically a period in which the infected person has no disease symptoms. The asymptomatic period can last as long as 10 years.
The question then arises, what is happening during this asymptomatic period? Many investigators believed that the virus was quiescent or latent during this period, as in other viral diseases such as herpes infection, in which the virus hides out in nerve ganglia and only becomes active for brief periods. One method of determining whether the virus is active is to perturb the host-virus system during the asymptomatic period. Fortunately, means are available for doing so.
In 1994, when the modeling work to be discussed in this review began, potent anti-retroviral drugs, the protease inhibitors were being developed and tested. Giving an antiretroviral drug to a patient is a means of perturbing the system. Working with David D. Ho, Aaron Diamond AIDS Research Center, we examined the response of 20 patients to a protease inhibitor, ritonavir. The results were dramatic. As shown in Figure 1 .2, the amount of virus measured in blood plasma fell rapidly once the drug was given. Plasma viral load before and after treatment with a protease inhibitor, showing rapid decline in viral concentrations after treatment initiation at t = 0. Each HIV-1 virus particle contains two RNA molecules. Data is from two out of 20 patients studied in 23]. All 20 patients exhibited similar rapid declines (see Table 1 ).
2. The simplest HIV dynamic model. Although previous modeling work had generated a large number of intricate models of HIV dynamics within individual patients, the data obtained from this perturbation experiment would not support the application of a complicated model. The data appeared to show that the virus concentration fell exponentially for a short period after a patient was placed on a potent antiretroviral drug. Thus, the following model was introduced, dV dt = P ? cV ; (2.1) where P is an unknown function representing the rate of virus production, c is a constant called the clearance rate constant, and V is the virus concentration. If the drug completely blocks viral production, i.e., causes P = 0, then the model predicts V will fall exponentially, i.e., V (t) = V 0 e ?ct ; where t = 0 is the time therapy is initiated and V (0) = V 0 . Plotting ln V vs t and using linear regression to determine the slope allowed us to estimate c, and the half-life of virus in the plasma, t 1=2 = ln 2=c. The notion that virus concentration attains a set-point suggests that before therapy began, the patient was in a quasi-steady state in which dV=dt = 0. If this were the case, as our data on these patients suggested (see Figure 2 .1 for three examples), then by knowing c and the initial virus concentration V 0 , we could compute the viral production rate before therapy, i.e., P = cV 0 . Measuring V 0 for each patient, then multiplying this concentration by the uid volume in which virus is expected to be found, allowed us to compute the total rate of virus production in these patients. These results are summarized in Table 1 . The rates are minimal estimates because they are based on the hypothesis that the drug completely blocks virus production and hence that the kinetics after drug therapy is initiated is a perfect exponential decline. Although the data appeared to fall exponentially, we knew on theoretical grounds that this could not be the case, because the drug could not instantly block all viral production. Thus, our experiments measured the rate of virus clearance in the face of some residual production, and the slope of the viral decline was not the true clearance rate constant, but only a lower bound. More re ned models given below will illustrate this point. Further, we believe that the viral clearance we measured was a consequence of biological processes in place before drug was given, since similar rates of decline have been observed with di erent drugs and with di erent patient populations (cf. 9, 65]). In the presence of HIV, T cells become infected. The simplest and most common method of modeling infection is to augment (3.1) with a \mass-action" term in which the rate of infection is given by kV T, with k being the infection rate constant. This type of term is sensible since virus must meet T cells in order to infect them and the probability of virus encountering a T cell at low concentrations (when V and T motions can be regarded as independent) can be assumed to be proportional to the product of their concentrations. Thus, in what follows, we shall assume that infection occurs by virus, V , interacting with uninfected T cells, T, causing the loss of uninfected T cells at rate ?kV T and the generation of infected T cells at rate kV T.
CD4
In principle, the rate of infection should saturate at high virus concentration. However, during HIV infection the concentration of virus never gets high compared to the number of T cells. In fact, in the blood of an HIV-1 infected patient a typical ratio might be 1:1 (e.g. 10 5 virions/ml and 100 CD4 + T cells/ l). Similarly, it has been estimated that there are approximately 10 11 virions and 10 11 CD4 + T cells in lymphoid tissue 6]. Thus, we ignore saturation e ects. Infection might also occur by cell-cell transmission, where an infected cell, T ? , directly interacts with an uninfected cell, T. There is little evidence that such direct cell-cell infection is a major pathway in vivo and we shall ignore this mode of infection here.
The models that we focus on are one-compartment models in which V and T are identi ed with the virus concentration and T cell counts measured in blood. Infection is not restricted to blood, and in fact, the vast majority of CD4 + T cells are in lymphoid tissue. However, the available data suggests that the concentration of virus and CD4 + T cells measured in blood is a reasonable re ection of their concentrations throughout the body (cf. 19, 51]), as one would expect for a system in equilibrium. Clearly transients may develop, say due to an acute infection, when this is no longer the case. Multi-compartment models are being developed (cf. 28, 31] (3.3) dT ? dt = kV T ? T ? ; (3.4) dV dt = N T ? ? cV:
The various terms and parameters are described below.
The probability that an infected (or uninfected) lymphocyte dies as a function of time or cell age is not known. Thus, we have made the simplest possible assumption, that is, that the rate of death per cell is a constant d T for uninfected cells and for infected cells. This is equivalent to the assumption that the probability of cell death at time t is given by an exponential distribution with an average cell lifetime of 1=d T for uninfected cells and 1= for infected cells. Other models might incorporate a density-dependent rate of death or use some other intrinsic probability distribution for cell death. For example, one might imagine that the probability of cell death is given by a gamma distribution, which is used to represent multistage processes and can be viewed as suggesting that cell death only occurs after a number of sub-processes are completed. Because distributions like the gamma distribution are speci ed by two or more parameters, they are not useful at this stage in modeling where there is no basis for choosing these parameters or any possibility of identifying them from data. Later we will show that from data we can estimate the mean, 1= , of the probability distribution describing cell death.
In the presence of HIV there are two types of T cells, uninfected and productively infected. Thus, it would be reasonable to change the logistic proliferation term to pT(1 ? T+T ? Tmax ). However, the proportion of productively infected cells is very small, on the order of 10 ?4 to 10 ?5 of T cells 7], and thus it is sensible to ignore this correction.
Finally, virus is produced by productively infected cells. Here we have assumed that on average each productively infected cell produces N virions during its lifetime.
Since the average lifetime of a productively infected cell is 1= , the average rate of virion production is = N . In some models it is useful to introduce the parameter , while for other purposes it is easier to think about (and measure) the total number of virions produced by a cell during its lifetime, N.
In this equation we have ignored the loss of virus due to infection of a cell. Each time a cell is infected at least one virion must enter and thus one might add the term ?kV T to (3.5) . In examining the rate of clearance of virions from patients with di erent T cell counts, we did not nd any statistically signi cant correlation with the T cell count 23]. Thus, it appears as if the term kTV is small compared to cV in the average HIV-infected patient. Also, if T is approximately constant then one can de ne a new clearance rate constant, c 0 = c + kT, that incorporates loss of virus by infection and other clearance processes. For these reasons we shall not include a ?kV T term in (3.5).
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The mechanism of virus clearance from the blood is not known. In fact, binding to cells may be an important part of the clearance mechanism. Thus, one might want to add not only a ?kV T term to equation (3.5) If c < NkT 0 , then 1 > 0, 2 < 0, the origin is a saddle point, and the virus will grow without bound. When c > NkT 0 , the eigenvalues are both negative and the virus will ultimately go extinct. Heuristically, the condition c > NkT 0 can be viewed as implying that the rate of clearance of the virus is greater than its rate of production. At the time of initial infection it is reasonable to assume that T = constant. Thus, if one is infected with a virus with parameters Nk, such that c > NkT 0 , this theory predicts that the virus will be eliminated and the infection will not take. Interestingly, when health care workers are stuck by needles contaminated with blood from AIDS patients the frequency at which such people become HIV positive is very low, maybe 1 in 200 such incidents. Similarly, not every sexual encounter between an HIV-infected person and an uninfected partner results in detectable infection. Both of these observations are consistent with the prediction that not all infections take. However, the ability to clear the virus by an person diagnosed as being infected should not be taken as an established fact. A variety of other experiments have shown that if the virus load ever gets high enough to be reliably measured, i.e., high enough to reliably establish that a person has been infected, then it is extremely unlikely that the virus will ever be cleared spontaneously.
When c = NkT 0 , the two lines in the phase-plane coincide and there exists a line of equilibria with eigenvalues 1 = ?( + c) and 2 = 0; no single point is stable but rather the entire line is a set of possible equilibria. If a perturbation drives the system o the line, then the system will return to another equilibrium point on the line. Thus, the state of the system could wander along the line. If c were not exactly equal to NkT 0 , say somewhat smaller, then this wandering would slowly lead to an increase in virus. While the existence of a quasi-steady state value for the viral load is well established, there is still a tendency for the viral load to increase, possibly by a few percent a year. Thus, while c = NKT 0 is the condition for a quasi-steady state, slight variations from this will keep the viral load trajectories between the two lines given by (3.11).
The nding of a manifold of equilibria when c = NkT 0 is noteworthy because it allows for the possibility of the stable maintenance of productively infected cells, T ? , and virus, V , at nite positive values. Further, depending on the parameters characteristic of the virus and host, the equilibrium can di er from one patient to the next. This is also true in the more complex three-dimensional system in which the target cell population is allowed to vary. However, because the T cell level in patients generally changes very slowly, substantial insight can be gained from analyzing the simpler two-dimensional system with T held constant and the parameter constraint c = NkT 0 .
In much of what follows we shall examine the e ects of perturbing this twodimensional system by applying drugs that a ect viral replication or viral infectivity. We shall show that analyzing data obtained for a period of one to two weeks following initiation of therapy, so that the assumption T = constant = T 0 is reasonable, has yielded important insights into the dynamics of HIV infection. 4 . HIV biology and drug therapy. HIV is an RNA virus. However, when it infects a cell the enzyme reverse transcriptase, which it carries, makes a DNA copy of its RNA genome. This DNA copy is then integrated into the DNA of the infected cell with the help of another virally encoded enzyme, integrase. The viral DNA, called the \provirus," is then duplicated with the cell's DNA every time the cell divides. Thus a cell, once it contains integrated provirus, remains infected for life. The provirus may also remain in the cytoplasm of the cell in unintegrated form. Ultimately this DNA is degraded and thus cells with unintegrated provirus are only transiently infected. A model incorporating transient infection has been developed 15] but will not be discussed here.
Within a T cell the provirus can remain latent, giving no sign of its presence for months or years 24, 16, 69] . Stimulation of the T cell by an antigen or a mitogen can lead to the production of new virus particles that bud from the surface of the infected cell. The budding can take place slowly, sparing the host cell, or it can take place very rapidly, possibly leading to the lysis of the T cell 35].
When new virus particles are produced by an infected cell the viral DNA is read and viral RNA is made. Some of this RNA is kept as a full length transcript of the viral DNA and is used as the genetic material packaged into new virus particles. Other RNA copies play the role of messenger RNA and are used as templates for making viral proteins. Without going into detail, many viral proteins, including the enzymes reverse transcriptase, protease and integrase, are made as one long \polyprotein", which must then be cleaved by viral protease into single proteins.
Current drug therapies for HIV-infected patients involve inhibiting either reverse transcriptase (RT) or HIV protease. If RT is inhibited, HIV can enter a cell but will not successfully infect it; a DNA copy of the viral genome will not be made and the cell will not make viral proteins or virus particles. The viral RNA that enters the cell is not stable and will degrade. If HIV protease is inhibited, cleavage of the viral polyprotein will not occur, and viral particles will be made that lack functional reverse transcriptase, protease and integrase enzymes. The net e ect of blocking HIV protease is that defective or "non-infectious" viral particles are made. The third viral enzyme, integrase, is also a potential target of drug therapy, and a number of pharmaceutical companies are trying to develop integrase inhibitors. Before therapy is initiated, V NI (0) = 0 and all virus belongs to the \infectious pool", i.e., V I (0) = V 0 . Thus, V I (t) = V 0 e ?ct , and as infectious virus decays the uninfected T cell population, T(t), increases, ultimately returning to the steady state it had in the absence of viral infection (again assuming that infection has not caused any of the parameters characterizing the T cell population to change).
Over a short period of time, immediately after therapy is initiated, one can assume that T = constant = T 0 . Making this assumption and substituting V I (t) into the 55] . The protease inhibitor ritonavir was administered orally (1200 mg/day) to ve HIV-infected patients, whose baseline CD4 cell counts and viral loads are shown in Table 2 . HIV-1 RNA levels in plasma were measured after treatment at frequent intervals. Each HIV virus particle contains two RNA molecules and thus the HIV-1 RNA level is a direct measure of the virus concentration, V . As shown in Figure 5 .1, each patient responded with a similar pattern of viral decay, with an initial lag followed by an approximately exponential decline in plasma viral RNA. Table 2 . Summary of HIV-1 clearance rate, infected cell loss rate, and virion production rate for three patients. Baseline values are measured from one week prior to administration of drug.
After ritonavir was administered, a delay in its antiviral e ect was expected due to the time required for drug absorption, distribution, and penetration into the target cells. This pharmacokinetic delay could be estimated by the time elapsed before the rst drop in the titer of infectious HIV-1 in plasma (Table 2; Figure 5 .2). However, even after the pharmacokinetic delay was accounted for, a lag of ' 1day was observed before the plasma viral RNA fell ( Figure 5 .1). This additional delay is consistent Table 2. with the mechanism of action of protease inhibitors, which render newly produced virions non-infectious but which inhibit neither the production of virions from already infected cells, nor the infection of new cells by previously produced infectious virions. These features of the action of a protease inhibitor are incorporated in our model and produce a \shoulder region" in which there is little initial viral decay.
Using nonlinear regression analysis, we estimated c, the viral clearance rate constant, and , the rate of loss of virus-producing cells, for each of the patients by tting (5.16) to the plasma HIV-1 RNA measurements after an adjustment of t = 0 was made to account for the pharmacological delay ( Table 2 ). The curves generated from (5.16), using the best-t values of c and , gave an excellent t to the data for all patients (Figure 5.1) .
Clearance of free virions was the more rapid process, occurring on a time scale of hours. The values of c ranged from 2.1 to 3.8 day ?1 with a mean of 3:1 0:6 day ?1 ( Table 2 ). The corresponding half-life, t 1=2 , of free virions (t 1=2 = ln 2=c) ranged from 0.2 days to 0.3 days with a mean of 0:24 0:06 days ( 6 hours). Because data was collected every 2 hours for the rst 6 hours and then every 6 hours until day 2, there were not very many data points contributing to the estimate of c, and large con dence intervals resulted 55]. In order to con rm that viral clearance was as rapid as predicted by this model, an additional experiment was done in which the Table 2 ). Note that the lifespans of productively infected cells, 1= , were not dramatically di erent among the study subjects, even though patients with low CD4 lymphocyte counts generally had decreased numbers of virus-speci c cytotoxic T cells that in principle can kill productively infected T cells 5].
5.3. Viral Production. At steady state, the production rate of virus must equal its clearance rate, cV 0 . Using the estimate of c and the pretreatment viral level, V 0 , we can obtain an estimate for the rate of viral production before protease inhibitor administration. The product cV 0 gives the number of virions produced per ml of plasma per day. To compute the total number of virions produced per day we multiply cV 0 by the total uid volume that virions are expected to be suspended in.
A typical 70 kg man has a uid volume of about 15 liters. Table 2 gives an estimate of each patient's viral production based on a calculation of plasma and extracellular uid volumes using the patient's body weight. The total daily viral production and clearance rates ranged from 0:4 10 9 to 32:1 10 9 virions per day, with a mean of 10:3 10 9 virions per day released into the extracellular uid (Table 2) . These estimates are still minimal estimates, since they are based on the assumption that ritonavir totally blocked all infectious virus production. Additional infection and viral production is probably occurring, and thus the true viral clearance rate is expected to be higher than our estimate. Further, not all virus that is produced is in extracellular uid, and the estimate does not take this into account. While this solution is more complex than that given by (5.16), it reduces to the simpler form when PI = 1. This can be seen by using the substitution for 1 ? PI given above coupled with l'Hôpital's rule, and noting that when PI = 1, 1 = ? and 2 = ?c. then therapy will not be e ective and the virus will continue to grow. Notice that if PI = 1, then, as we have already shown, the stability analysis predicts the virus will always be eliminated since the eigenvalues become 1 = ?c; 2 = ? ; 3 = ?c. For PI = 1 the solution (5.16) contains a secular term which for small enough values of c allow for a growth in the viral population before decaying to zero. The decay of V (t) is monotonic if c NkT 0 and when c < NkT 0 , the virus is increasing when therapy is initiated, and will continue to increase for a while under therapy, as illustrated in Figure 5 .4. The parameter estimates in Table 2 show that c , so that we can expand the square root to obtain 1 which is an Airy equation for which analytical solutions are known. Hence using the initial conditions and numerical evaluation methods we have an explicit solution to compare with experimental data. Figure 5 .6 shows the solution and its t with experimental data from three patients. Interestingly, explicitly taking the change in CD4+ T cells that occur over the course of one week of therapy into account has little e ect on the overall change in HIV-1 RNA.
Now consider the case where T is varying non-linearly due to both a source and proliferation. The equations we study are given by (5.17) . Because the equations are nonlinear we can not solve them explicitly. However, we note that the solution trajec- At any given time, t, the mean number of \blue" virions produced from the initial V 0 \red" virions is V NI (t). If we let P(t) be the (cumulative) probability that a virion is produced by time t, then P(t) = V NI (t)=V 0 . The probability density of a virus being 6. Drug Resistance. The fact that > 10 10 virions are produced each day in the average mid-stage HIV-1 infected patient has signi cant implications for the generation of drug resistance. When HIV replicates, its RNA genome is reverse transcribed into DNA. This copying process is error-prone, and in vivo the error rate has been estimated as 3 10 ?5 per base per replication cycle 36]. The HIV-1 genome has approximately 10 4 bases, and thus the average number of changes per genome is 0.3 per replication cycle. According to the binomial distribution or its Poisson approximation, we then expect after one replication 74% of infected cells to carry unmutated genomes, 22% of infected cells to carry genomes with one mutation, 3.3% to carry two mutations, 0.33% to carry three mutations, and so on (Table 3) .
Not all 10 10 virions produced per day will infect other cells. Some will be defective; others, even if infectious, will be cleared. If, as suggested by Haase et al. 19] , about 100 virions are produced per productively infected CD4 + T cell, then at steady state only one of these 100 virions should go on to successfully infect another cell and produce a new generation of virions. (Recent, unpublished data from P. Bucy, University of Alabama, suggests that this estimate of 100 virions may be an order of magnitude too low. However, even if true it will not change the conclusions reached below.) If one productively infected cell led to the productive infection of more than one other cell, then the infection would not be in steady state and the number of virions would be increasing. If we assume that one out of a hundred virions infect another cell, then on average there are 10 8 new infections per day. Hence, as shown in Table 3 , we expect on average 0:22 10 8 mutants to be generated per day with single base changes. Because each of the 10 4 bases in HIV-1 could mutate to any of 3 other bases, there are a total of 3 i ? n i possible sequences of length n with i mutations.
Thus, with n = 10 4 , there are 3 10 4 possible single base mutants, and essentially all of them would be generated each day. Consequently, resistance to drugs, such as 3TC, which only require a single base change is expected to occur rapidly and does 60]. In our initial studies with ritonavir 23], virus plasma levels fell to approximately 1% of their pretreatment values in 2 weeks. However, in 18 out of 20 patients the decrease in virus was not maintained for long periods and the viral load rebounded. Genetic analysis suggests that one of the key resistance mutations for the protease gene, a valine to alanine substitution at position 82, pre-existed 13], as predicted by these calculations. A similar pattern of rapid emergence of drug resistance to HIV-1 reverse transcriptase inhibitor nevirapine has also been seen 20 Table 3 , adapted from 52]. Assuming that the HIV genome is approximately 10 4 base pairs long and that reverse transcriptase introduces errors into the HIV genome at a rate of 3 10 ?5 per base pair per generation, the Table shows the probability of an infected cell containing a proviral HIV genome with 0, 1, 2, or 3 mutations in it. Further, assuming 10 8 new cells are infected each day, the expected number of such mutants created each day within one infected individual is given. Lastly, we have also computed the fraction of all possible mutants with 1, 2, or 3 mutations that are created each day. If, for example, only one particular triple mutant gave rise to drug resistance then the probability of it being generated in a given patient on any given day from a wild-type virus is 7:4 10 ?8 .
The chance of a mutant arising with a particular two base change, while substantially lower, is not so low that it can be neglected. The rate of generation of double mutants is 3:3 10 6 /day or 0.74%/day of the possible two-base mutants (Table 3) . Because a number of mutation combinations can lead to resistance, there is a reasonable chance that two-base mutants that could confer drug resistance pre-exist or will appear. In fact, in a population of size 1=7:4 10 ?3 = 135 one would expect every possible double mutant to be created on average each day. Although we have not modeled mutant survival, we would expect many of these mutants to survive and be able to grow in the presence of drug. Thus, in a large population, many recipients of drug will show resistance if only two mutations are required. Models which explicitly take into consideration the generation and growth of mutants have been developed 3, 4, 47, 61, 66] and will not be reviewed here.
For three-base change mutants, the situation is di erent. In single replication cycles, less than 10 ?7 of all possible three-base mutants are generated per day (Table 3) . Thus, it is extraordinarily unlikely that any particular three-base change mutant will arise spontaneously. However, such mutants can be selected by sequential mutations if one or two-base mutants replicate.
7. Combination Therapy. The results of the last section suggest that therapy using a single drug is doomed to fail because of drug-resistance. Thus, in order to sustain a long-term response, models predict, and experience has borne out, that combination therapy is needed. Since both reverse transcriptase (RT) and protease inhibitors are available, most combination therapies employ both types of inhibitors in order to block the viral life cycle at two independent points.
In a clinical trial employing a protease inhibitor, nel navir, and two reverse transcriptase inhibitors, AZT and 3TC, novel dynamics were observed after therapy was initiated 51]. As with a single drug, the virus concentration in plasma fell dramatically for one to two weeks. However, under continued therapy, after this initial` rst phase' of decline, the virus continued to fall but at a signi cantly slower rate. When the virus concentration was plotted on a logarithmic scale, the two-phases of viral decline were both seen to be approximately exponential, as displayed in Figure 7 .1. The question then arose, why did the virus not continue to fall at the rapid rstphase rate? The antiretroviral e ect of the combination therapy was potent in that the concentration of HIV-1 in plasma dropped below the standard detection threshold of 500 copies/ml by 8 weeks of treatment, and was found to be <25 copies/ml at week 16-20 using an ultrasensitive assay. Further, there was no evidence of emergence of drug-resistant virus during the 16-20 week study period, suggesting that the second phase of decay has a biological origin.
In the presence of both RT and protease inhibitors our basic model, with T = constant = T 0 , takes the form dT ? dt = (1 ? RT )kV I T 0 ? T ? ; (7.1) dV I dt = (1 ? PI )N T ? ? cV I ; (7.2) dV NI dt = PI N T ? ? cV NI ; (7.3) where RT and PI are the e ectiveness of the RT and protease inhibitors, respectively. If both the protease and RT inhibitors are 100% e ective, then the model simpli es to dT ? dt = ? T ? ; (7.4) dV I dt = ?cV I ; (7.5) dV NI dt = N T ? ? cV NI ; Hence, one would expect that after a rapid transient of the order of 1=c, the viral load would fall exponentially at a rate characterized by the constant . This fall corresponds to the rst phase decline observed in the data.
Although there are many possible explanations for the second phase of plasma virus decline, we shall restrict our attention to those that we believe are the most plausible. First, if there were a source of virus other than infected cells, then the virus concentration, rather than falling continually, would ultimately come to a new steady state in which production by this source was in balance with clearance. If the source, rather than being constant, decayed slowly, then the virus concentration would exhibit a second phase decline whose rate re ected the rate of decay of the source.
In addition to CD4 + T cells, other cells are known to be susceptible to HIV-1 infection. One such pool of cells are macrophages, large cells that reside in tissue and which can engulf various biological debris. A fraction of these cells are CD4 + , and in cell culture they become productively infected by HIV-1. Furthermore, HIVinfection in cell culture tends not to kill macrophages, and they are able to produce virus particles for weeks in culture. Another possibility is that the pool of T cells is heterogeneous, with a subpopulation of T cells upon infection producing fewer Before treatment is initiated we shall assume that patients are in quasi-steady (7.13) dT ? dt = ? T ? ; (7.14) dM dt = s M ? d M M; (7.15) dM ? dt = ? M M ? ; (7.16) dV I dt = ?cV I ; (7.17) dV NI dt = N T ? + p M M ? ? cV NI : (7. 18)
The equations for T and M decouple from the equations determining viral dynamics, and hence the assumption that T or M remains constant after therapy need not be made. Because the viral dynamic equations are linear, the following solution can be obtained in a straightforward manner.
T ? (t) = T ? 0 e ? t ; (7.19) M (t) = M 0 e ? M t ; (7.20) V I (t) = V 0 e ?ct ; (7.21) V Using nonlinear least squares regression we tted the patient data obtained in this combination therapy clinical trial to the long-lived infected cell model and estimated three parameters: , M , and the composite parameter, NkT 0 . Virion clearance occurred too rapidly to estimate c from the data obtained in this study. Thus c was held constant at the mean value, c =3 day ?1 , determined in 55]. The parameter M , which determines the lifespan of the long-lived infected cells, ranged from 0.03 to 0.12 day ?1 , with a mean value of 0.07 0.04 day ?1 . The half-life of the cell population responsible for the second phase of viral decay, t 1=2 = ln2= M had a mean value of 13.3 days, with a standard deviation of 7.9 days. The theoretical curves generated from (7.23), using the best-t parameter values gave an excellent t to the data for all patients (see One di erence between the long-lived cell model and the trapped virion model is that virions released from tissues would be virions trapped before therapy was initiated and hence should be infectious rather than noninfectious. Thus, it might be possible to distinguish this model from the long-lived cell model experimentally. So far, this has not been possible due to technical di culties in analyzing the low concentration of virions that can be obtained during the second phase. The models could also be distinguished if trapping of virions were occurring at an observable rate during therapy. We are currently examining more detailed models of viral transport between blood and lymphoid tissue, with reversible binding of virus particles to follicular dendritic cells. The latently infected cell model also gives predictions for the best-t value of , the short-lived infected cell lifetime, that are indistinguishable from the values obtained from the long-lived infected cell model. Using the best-t parameter values, the theoretical curves predicted from (7.25) are indistinguishable from those predicted by (7.23) . Hence, both the latently infected cell model and the long-lived infected cell model make identical predictions for the course of second-phase decay. However, the two models can be distinguished by the use of additional experimental information. In a system where a population of latently infected cells is responsible for the second phase of viral decay, an increase in the activation rate of resting cells could signi cantly alter the decay behavior. Such an increase could be caused by, for example, natural infection, vaccination, or arti cial stimulation of the immune system by some type of immunotherapy. Thus, immune stimulation administered during the second phase of viral decay for a patient with inhibitor e ectiveness approaching 100% could provide important information concerning the mechanism of viral decay. Following a signi cant immunogenic challenge, the latently-infected cell model predicts an increase in viral burden followed by an accelerated decay and subsequent clearance of infection, or a return to second phase type decay, depending on the magnitude of the immunogenic challenge as shown in Figure 7 .2, while the long-lived productivelyinfected cell model predicts no change in the slow second phase decay. Preliminary experiments in which patients were vaccinated during the second phase did not show a statistically signi cant increase in viral load. Further experiments are planned in which more potent immunostimulation is given.
We have shown that measuring the viral load in blood after initiation of an-tiretroviral treatment does not provide su cient information to identify the biological processes underlying the second-phase of viral decline. This conclusion, which was taken seriously by our experimental collaborator David Ho, led i : (7.27) Fitting experimental data to the combined model gave estimates of the most important parameters. Details can be found in 51]. This analysis suggested that while both latently infected and long-lived cells contribute to the second phase, long-lived infected cells are the major source of second-phase virus. Estimating the total possible body burden of long-lived infected cells to be between 10 9 and 10 12 , and assuming that the second phase decays with a half-life of four weeks, the slowest rate among the patients studied in 51], we estimated that on average it would take between two and a half and three years of perfectly e ective treatment to allow the cells responsible for the second-phase to completely decay, and V to approach zero in this model. These estimates, when presented in preliminary form at the XIth International Conference on AIDS in Vancouver in 1996 53], generated a lot of enthusiasm and optimism. It was hoped that if patients were kept on drugs for two to three years that the virus might be eradicated. More importantly, it established that even though the amount of viral RNA went undetectable in patients after some months of combination therapy, patients need to remain on therapy for at least a few years to allow the cells responsible for the second phase to decay. 8 . Discussion. In this paper we have tried to show how mathematical modeling has impacted our understanding of HIV pathogenesis. Before modeling was brought to bear in a serious manner, AIDS was thought to be a slow disease in which treatment could be delayed until symptoms appeared and patients were not monitored very aggressively. In the large multicenter AIDS cohort studies aimed at monitoring the natural history of the disease, blood typically was drawn every six months. There was a poor understanding of the biological processes that were responsible for the observed levels of virus in the blood and the rapidity at which the virus became drug resistant. Modeling, coupled with advances in technology, has changed all of this. In section 2, we showed how an extremely simple model involving a single linear ordinary di erential equation, when applied to the interpretation of clinical data obtained in a phase I/II drug trial, gave the rst quantitative estimate of how rapidly HIV was being produced and cleared in an infected person. While the mathematics involved was trivial, the application of mathematics in this manner was novel, and set o what has been described as a revolution in thinking about HIV. The papers by Ho et al. 23] and Wei et al. 65 ] that were published in the same issue of Nature and which both reported an approximately 2 day half-life for HIV in plasma were the most highly cited scienti c papers published in 1995.
A more complex model presented in section 3 that incorporated both virus and infected cells, when compared with data collected to test the model, showed that the two day viral half-life mainly re ected the lifetime of infected cells that produced virus. Thus, the rst estimate of the lifetime of a productively infected cell in vivo was obtained, which allowed us to think in a more quantitative manner about the issue of CD4 + T cell depletion, the hallmark of AIDS. Further, the estimate of the rate of clearance of free viral particles was improved and the half-life of free virus particles in plasma is now estimated at 6 hours or less. Because the level of virus is maintained at steady-state, the rate of viral clearance can be used to determine how rapidly HIV is produced. Doing these calculations led to the conclusion that in an average HIV-infected person at least 10 10 virus particles are produced and released into bodily uids each day. As explained in section 5.6, these estimates can be used to calculate a viral generation time of approximately 1.8 days. This implies that in an infected person HIV can go through about 200 replication cycles per year, with the possibility of mutating at each replication. Thus, the rapid evolution of HIV can easily be understood. The practical implication of this was that therapy with a single drug in which a few mutations were all that were required for resistance to arise could be shown to be a poor strategy. This helped herald in the current strategy of combination therapy and the approach of treating HIV infected persons as soon after diagnosis as possible.
Using more complex models, involving multiple cell populations, has allowed further interpretation of clinical data obtained from patients on combination therapy in which the virus concentration in plasma has a two-phase decline. This work, described in section 7, has also had important practical consequences. By extrapolating in a rigorous way the data obtained from patients responding well to combination therapy we were able to estimate how long therapy would need to be given to clear the cells responsible for producing the observed levels of virus. While bringing home the lesson that therapy would need to continue for years after free virus became undetectable in blood, the work also began the process of quantifying both the level and role of latently infected and long-lived infected cell populations in HIV infection.
Throughout this paper we have analyzed situations in which models predict that under su ciently intense therapy, the virus and infected cell concentrations will go to zero. The question then arises, is viral eradication a realistic expectation? At the moment, we do not know. Clearly, the models that we have analyzed are only simpli ed caricatures of reality. They have not included the spatial and compartmental aspects of the body, and have implicitly assumed that drug is available everywhere in the body at a constant e ectiveness. Not all drugs penetrate the blood-brain barrier e ectively, and thus drug concentrations in the brain and central nervous system tend to be lower than in the circulation. Also, the cells of the immune system have limited access to these sites, and hence the brain and other sites with poor drug penetrance, such as the testes, may act as sanctuaries for the virus. Not surprisingly, in models with drug sanctuaries it is easier to generate drug resistance 28], and hence ongoing viral replication may remain a problem until a new generation of drugs become available.
The models have only dealt with the major targets of HIV infection, CD4 + T cells and macrophages. However, other cells may become HIV-infected and exhibit di erent kinetics. We have only dealt with infection of cells by free virus and the death of cells due to viral infection. Direct cell-to-cell transmission of virus has been reported in cell culture, as has death of cells due to e ects other than direct viral killing. All of these features may play a role in the long-term behavior of HIV-1 in vivo.
Another large omission in our models has been the immune response. Processes such as the death of virally infected cells and/or the clearance of free viral particles may have an immune component. Furthermore, viruses can evolve to become more pathogenic and drug resistant. Thus, parameters in our models, rather than being constant, as we have assumed, may vary in time and depend in some complex way on events occurring in the host. Many of us hope that drugs will not need to be given until every last viral particle and infected cell is eliminated, but rather that as the amount of virus is reduced by antiretroviral drugs, recovery of the immune system will occur, and the host defense system will ultimately be able to control or clear any remaining virus. Both models and experiment are needed to examine this possibility.
Potent combination therapy has been available for 2 to 3 years. Analysis of lymphocytes from blood and tissue biopsies have shown that small numbers of latently infected cells can be found in patients treated for as long as 2.5 years 16, 69] . Whether the immune system can control the remaining infection is not known, and thus cessation of antiretroviral treatment is not recommended. The rate at which latently infected cells are decaying, and particularly those carrying proviruses that can generate infectious particles on stimulation, is also not yet known although there are some suggestions that they may have a half-life of 3 -5 months 22]. Making estimates of the pool size of latently infected cells one can surmise that 5 to 7 years of continuous therapy may be required to achieve eradication of latently infected CD4 + T cells 22]. This is an unacceptable solution due to the complexity of complying with current drug regimes, drug side e ects and cost. Alternative approaches are needed and are being examined 22].
Models, such as the ones discussed here, have been developed and tested on data obtained over relatively short periods: days, weeks, and in some cases months. Even though the models appear accurate on these time scales, they should not be used to predict the long-term events in individual patients. They have provided much insight into the biological events underlying the disease process, and have helped guide treatment strategies. Eradicating HIV from an infected patient or helping the body control the infection still remains our goal. We believe that modeling will continue to play an important role in attaining this goal.
